BerganKDV Wealth Management LLC boosted its position in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 4.4% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 44,912 shares of the company’s stock after acquiring an additional 1,904 shares during the period. Johnson & Johnson comprises 0.9% of BerganKDV Wealth Management LLC’s investment portfolio, making the stock its 24th biggest holding. BerganKDV Wealth Management LLC’s holdings in Johnson & Johnson were worth $7,934,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. AIA Group Ltd boosted its holdings in shares of Johnson & Johnson by 69.3% in the 4th quarter. AIA Group Ltd now owns 51,544 shares of the company’s stock valued at $9,105,000 after buying an additional 21,104 shares in the last quarter. Bickling Financial Services Inc. raised its position in Johnson & Johnson by 3.0% in the 4th quarter. Bickling Financial Services Inc. now owns 4,820 shares of the company’s stock valued at $851,000 after purchasing an additional 142 shares during the last quarter. RWC Asset Management LLP purchased a new stake in Johnson & Johnson in the 4th quarter valued at $29,326,000. KCM Investment Advisors LLC raised its position in Johnson & Johnson by 0.3% in the 4th quarter. KCM Investment Advisors LLC now owns 282,341 shares of the company’s stock valued at $49,876,000 after purchasing an additional 850 shares during the last quarter. Finally, apricus wealth LLC raised its position in Johnson & Johnson by 1.0% in the 4th quarter. apricus wealth LLC now owns 17,415 shares of the company’s stock valued at $3,076,000 after purchasing an additional 168 shares during the last quarter. Institutional investors and hedge funds own 67.94% of the company’s stock.
Johnson & Johnson Price Performance
Johnson & Johnson stock opened at $162.69 on Friday. Johnson & Johnson has a 12-month low of $150.11 and a 12-month high of $186.69. The stock has a market capitalization of $423.69 billion, a P/E ratio of 34.04, a P/E/G ratio of 2.63 and a beta of 0.53. The firm’s 50-day moving average is $157.48 and its two-hundred day moving average is $166.96. The company has a debt-to-equity ratio of 0.35, a current ratio of 0.99 and a quick ratio of 0.77.
Johnson & Johnson Increases Dividend
The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 6th. Stockholders of record on Tuesday, May 23rd will be given a dividend of $1.19 per share. The ex-dividend date is Monday, May 22nd. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.93%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.13. Johnson & Johnson’s dividend payout ratio (DPR) is presently 94.56%.
Insiders Place Their Bets
In other news, insider James D. Swanson sold 1,062 shares of the business’s stock in a transaction on Monday, March 6th. The shares were sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the transaction, the insider now owns 9,215 shares of the company’s stock, valued at $1,425,191.90. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. 0.20% of the stock is currently owned by corporate insiders.
Analysts Set New Price Targets
A number of equities analysts have commented on the stock. Piper Sandler cut their price objective on shares of Johnson & Johnson from $55.00 to $52.00 in a research report on Monday, February 6th. StockNews.com initiated coverage on shares of Johnson & Johnson in a research report on Thursday, March 16th. They set a “strong-buy” rating for the company. UBS Group initiated coverage on shares of Johnson & Johnson in a report on Tuesday, March 28th. They issued a “neutral” rating and a $164.00 price target for the company. Guggenheim initiated coverage on shares of Johnson & Johnson in a report on Tuesday, February 28th. They issued a “neutral” rating and a $161.00 price target for the company. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a report on Wednesday, February 1st. Seven analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $173.00.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Read More
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- 2 Industrial Strength Dividend Stocks Melting Up
- Proctor & Gamble Is Going To Set A New High
- AutoNation’s Plans are Keeping Analysts Around
- Netflix Increases Buybacks: Can It Complete A Reversal In 2023?
- Why Philip Morris May Continue to Beat the Broader Market?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
